Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
27°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunocore Holdings Plc ADR
(NQ:
IMCR
)
32.28
+0.16 (+0.50%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunocore Holdings Plc ADR
< Previous
1
2
Next >
Immunocore to present at upcoming investor conferences
November 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports third quarter financial results and provides a business update
November 06, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at the 2024 Cantor Global Healthcare Conference
September 12, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces transition of Chief Financial Officer
August 29, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports second quarter financial results and provides a business update
August 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
August 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
June 18, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 31, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore reports first quarter financial results and provides a business update
May 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
April 04, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore presented two posters at CROI 2024
March 05, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
March 01, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
February 28, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
February 22, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
February 21, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Prices Upsized Convertible Senior Notes Offering
January 30, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Announces Proposed Convertible Senior Notes Offering
January 29, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
January 05, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
November 01, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
October 30, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
October 21, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces upcoming presentation and posters at ESMO 2023
October 06, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
September 11, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
